Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 6 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
12 Jan 2020
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.

Patients with idiopathic inflammatory myopathies at high risk of acute coronary syndrome

20 Nov 2019

The risk of acute coronary syndrome (ACS) is increased in individuals with idiopathic inflammatory myopathies (IIM), especially within the first year following diagnosis, according to a recent study.

The incidence rate of ACS was higher in IIM patients than in the general population, specifically among older individuals and within the first year of diagnosis. The overall incidence rate of ACS in IIM was 15.6 (95 percent confidence interval [CI], 11.7–20.4) per 1,000 person-years. Compared with the general population, those with IIM had a hazard ratio of 2.4 (95 percent CI, 1.8–3.2).

The increased risk of ACS in IIM individuals persisted even after accounting for the competing risk of death, with a cumulative incidence of 7 percent at 5 years compared to 3.3 percent in the general population.

This study sought to examine the risk of ACS in an IIM cohort vs the general Swedish population. The investigators identified 655 individuals with incident IIM and 6,813 general population comparators from national registries. IIM individuals were diagnosed between 2002 and 2011. Follow-up began at IIM diagnosis and corresponding date in the general population.

The International Classification of Diseases codes were used to define ACS, cardiovascular (CV) comorbidities and CV risk factors. The risk of ACS in IIM patients was compared with that in the general population using Cox proportional hazards models. Competing risk regression models were used to account for the competing risk of death.

“Evidence suggests an increased risk of CV diseases, including ACS, in IIM,” the investigators noted.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 6 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
12 Jan 2020
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.